Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria

A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria

The purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.

Study Overview

• Status: Completed
• Conditions: Primary Hyperoxaluria
• Intervention / Treatment: Biological: Oxabact OC5 capsules; Drug: Placebo capsules

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • Hôpital des Enfants, Centre de référence maladies rénales rares du Sud-Ouest (SORARE), CHU de Bordeaux
  • Lyon, France, 69677 Bron
    • Hôpital Femme Mère Enfant, Lyon - Paediatric Dept
  • Paris, France, 75015
    • Hôpital Necker-Enfants Malades,Centre de référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA)
  • Cedex 19
    • Paris, Cedex 19, France, 75945
      • Hôpital Robert-Debré, Néphrologie Pédiatrique
• Germany
  • Bonn, Germany, DE-53113
    • Universitätsklinikum Bonn, Dept of Paediatric Nephrology
• United Kingdom
  • Birmingham, United Kingdom, B4 6NH
    • Birmingham Children's Hospital NHS Foundation Trust - Dept of Nephrology
  • London, United Kingdom, NW3 2QG
    • Royal Free Hospital -UCL Centre for Nephrology
  • London, United Kingdom, WCIN 3JH
    • Great Ormond Street Hospital for Children NHS Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed informed consent (as applicable for the age of the subject).
• Male or female subjects ≥ 2 years of age (Germany & France) / Male or female subjects ≥ 5 years of age (United Kingdom)
• A diagnosis of PH type I, II or III (as determined by standard diagnostic methods).
• A mean urinary oxalate excretion of > 1.0 mmol/24h/1.73m2, based on at least three eligible urine collections performed during baseline (weeks 1-4).
• Renal function defined as an estimated GFR ≥ 40 ml/min normalised to 1.73m2 body surface area, or a creatinine clearance of ≥ 40 ml/min normalised to 1.73m2 body surface area.
• Subjects receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must not change the dose during the study. Subjects not receiving vitamin B6 at study entry must be willing to refrain from initiating pyridoxine during study participation.

Exclusion Criteria:

• Inability to collect complete 24-hour urine samples. Each urine collection will be evaluated for completeness based on urine qualitative criteria.
• Inability to swallow size 4 capsules twice daily for 8 to 10 weeks.
• Subjects that have undergone transplantation (solid organ or bone marrow).
• The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome.
• Use of antibiotics to which O. formigenes is sensitive, including chronic use, a history of more than two courses of antibiotic use during the past 6 months, current antibiotic use, or antibiotics use within 14 days of initiating study medication.
• Subjects who require immune suppressive therapy.
• Current treatment with ascorbic acid preparation.
• Pregnancy.
• Women of child-bearing potential who are not using adequate contraceptive precautions such as oral, transdermal, injectable, or implanted contraceptives, IUD, complete abstinence, use of a condom by the sexual partner, or sterile sexual partner.
• Presence of a medical condition that the Principal Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures.
• Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to screening or not willing to forego other forms of investigational treatment during this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Oxabact OC5 capsules; The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.	Biological: Oxabact OC5 capsules; The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.; Other Names: Oxalobacter formigenes
Placebo Comparator: Placebo capsules; The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.	Drug: Placebo capsules; An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in urinary oxalate levels from Baseline to week 8 of treatment.	8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in urinary oxalate levels from Baseline to week 8 of treatment in subsets of subjects	Change in urinary oxalate levels from Baseline to week 8 of treatment in subsets of subjects defined by: baseline urinary oxalate level, above and below 1.5 mmol/24h/1.73m2; concomitant vitamin B6 therapy and no vitamin B6 therapy; eGFR of ≥90 mL/min/1.73m2 (normal renal function) and < 90 mL/min/1.73m2 (mild to moderate reduction in renal function); age below 18 and age 18 or above	8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)
Number of subjects who reach urinary oxalate levels below 0.5, 0.7 and 1.0 mmol/24h/1.73m2 respectively from Baseline to week 8 of treatment.		8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)
Change in plasma oxalate levels from Baseline to week 8 of treatment.		8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)
Change in urinary oxalate levels from Baseline to week 4 of treatment.		8 weeks of active treatment (i.e. between Weeks 7 and 10 of the study)
Correlation between change in plasma oxalate levels and change in urinary oxalate levels, from Baseline to week 8 of treatment.		8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)
Change in number of O. formigenes in faeces from Baseline to week 8 of treatment.		8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)
Adverse events		8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)
Haematology	Blood samples taken for hematology at weeks 0, 5, 10 and 14. Complete blood count with differential and platelet count evaluated.	14 weeks (Throughout the study)
Clinical Chemistry	Blood samples taken for clinical chemistry at weeks 0, 5, 10 and 14. Blood Urea Nitrogen, creatinine, electrolytes (Na+, K+, Mg++, Ca++, HCO3+, Cl), glucose, pH, albumin, alkaline phosphatase, ALT, AST, total bilirubin and total protein evaluated.	14 weeks (Throughout the study)
Urinalysis	Urine samples will be taken at weeks 0, 5, 10 and 14 of the study. Protein, glucose and pH evaluated.	14 weeks (Throughout the study)

Collaborators and Investigators

• Sponsor: OxThera
• Collaborators: FP7-SME-2013 Research for the benefit of SMEs program
• Investigators: Principal Investigator: Bernd Hoppe, MD PhD, Universitätsklinikum Bonn, Dept of Paediatric Nephrology

Study record dates

Study Major Dates

• Study Start: December 1, 2013
• Primary Completion (Actual): January 1, 2015
• Study Completion (Actual): January 1, 2015

Study Registration Dates

• First Submitted: December 11, 2013
• First Submitted That Met QC Criteria: December 11, 2013
• First Posted (Estimate): December 17, 2013

Study Record Updates

• Last Update Posted (Estimate): October 16, 2015
• Last Update Submitted That Met QC Criteria: October 14, 2015
• Last Verified: October 1, 2015

More Information

Terms related to this study

• Keywords: hyperoxaluria; PH; oxalate
• Additional Relevant MeSH Terms: Metabolic Diseases; Kidney Diseases; Urologic Diseases; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Hyperoxaluria; Hyperoxaluria, Primary
• Other Study ID Numbers: OC5-DB-01